All In Biotech

Drug Trial Radar · NCT04994912

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Title of Study: A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Oct 1, 2021

Primary completion

Jan 7, 2025

Study completion Feb 18, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.

Conditions

  • Healthy

Interventions

  • EI-001Drug

    EI-001 IV infusion

  • PlaceboOther

    Placebo IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety assessmentTime frame: Day 1
  2. safety assessmentTime frame: Day 1
  3. safety assessmentTime frame: Day 1

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

  • Huashan Hospital of Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.